Loading clinical trials...
Loading clinical trials...
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of pDNA Vaccines Expressing HIV M Group p24^Gag Conserved Elements and/or p55^Gag, Administered With IL-12 pDNA, in Healthy, HIV-Uninfected Adult Participants
Conditions
Interventions
p24CE1/2 pDNA Vaccine
p55^gag pDNA Vaccine
+3 more
Locations
3
United States
Bridge HIV CRS
San Francisco, California, United States
The Hope Clinic of the Emory Vaccine Center CRS
Decatur, Georgia, United States
Case Clinical Research Site
Cleveland, Ohio, United States
Start Date
October 18, 2017
Primary Completion Date
October 25, 2019
Completion Date
April 29, 2020
Last Updated
February 7, 2024
NCT06627764
NCT06694805
NCT04142047
NCT07428330
NCT05398185
NCT07225530
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions